Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

Completed

• Conditions: Stage IIIB/IV; Non-Small Cell Lung Cancer

• Registration Number: NCT01525199
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.

Detailed Description

Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.

Study Timeline

• Study First Submitted: 2012-01-31
• Study First Submitted QC: 2012-01-31
• Study First Posted: 2012-02-02
• Study Start: 2012-05
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2014-04
• Last Update Submitted: 2014-04-11
• Last Update Posted: 2014-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV.
• Patients under 1st line treatment against lung adenocarcinoma.

Exclusion Criteria

• Patients not having the information required by the protocol.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	12 months after the diagnosis of advanced disease
Disease free survival	12 months after the diagnosis of advanced disease
Number of hospitalizations	12 months after the diagnosis of advanced disease

Trial Locations

Locations (1)

Research Site; 🇦🇷 Tucuman, Argentina